Patents by Inventor Xiaoxia Zheng
Xiaoxia Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240145712Abstract: A carbon material includes a porous carbon substrate and an amorphous carbon layer provided on at least part of a surface of the porous carbon substrate.Type: ApplicationFiled: January 10, 2024Publication date: May 2, 2024Inventors: Yu MA, Xiaoxia CHEN, Xiaoji ZHENG
-
Publication number: 20240074882Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric material wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable of expanding at body temperature in a body lumen from a crimped configuration to a deployed diameter and will have sufficient strength to support a body lumen when expanded.Type: ApplicationFiled: March 30, 2022Publication date: March 7, 2024Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20230293540Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: March 6, 2023Publication date: September 21, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Margaret Wong, Blaine Bueche
-
Publication number: 20230190499Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: ApplicationFiled: February 6, 2023Publication date: June 22, 2023Applicant: Elixir Medical CorporationInventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
-
Publication number: 20230165874Abstract: Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: January 27, 2023Publication date: June 1, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Blaine Bueche
-
Publication number: 20230165839Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: September 9, 2022Publication date: June 1, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 11654036Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: GrantFiled: August 13, 2021Date of Patent: May 23, 2023Assignee: Elixir Medical CorporationInventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
-
Publication number: 20220039976Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: ApplicationFiled: August 13, 2021Publication date: February 10, 2022Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan
-
Publication number: 20210008040Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, —OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: May 20, 2020Publication date: January 14, 2021Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10695327Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: October 8, 2018Date of Patent: June 30, 2020Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20200093619Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: February 20, 2018Publication date: March 26, 2020Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20190275013Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: October 8, 2018Publication date: September 12, 2019Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10123996Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: June 13, 2016Date of Patent: November 13, 2018Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20170156899Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: January 31, 2017Publication date: June 8, 2017Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20170119741Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: June 13, 2016Publication date: May 4, 2017Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 9566371Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: GrantFiled: July 21, 2015Date of Patent: February 14, 2017Assignee: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20160278953Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: June 9, 2016Publication date: September 29, 2016Inventors: Xiaoxia ZHENG, John YAN, Vinayak BHAT
-
Publication number: 20160213499Abstract: Biodegradable stent prosthesis are formed as a tubular body comprising a biodegradable polymeric material. The stent prosthesis are expandable from a crimped configuration to an expanded configuration and have a radial strength and a conformability.Type: ApplicationFiled: January 23, 2015Publication date: July 28, 2016Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20160175288Abstract: The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof.Type: ApplicationFiled: February 29, 2016Publication date: June 23, 2016Inventors: John Yan, Xiaoxia Zheng, Vinayak Bhat
-
Publication number: 20160067389Abstract: Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.Type: ApplicationFiled: November 18, 2015Publication date: March 10, 2016Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat